Israel’s aMoon II healthcare fund has closed at US$660 million – the largest amount raised by a life sciences and healthcare fund in the country.
The fund plans to invest in mid- to late-stage companies in digital health, medical devices and biopharma in Israel, the US and Europe. Commitments exceed the US$500 million planned for the fund.
The asset management and private banking arm of Swiss bank Credit Suisse came in with US$250 million a cornerstone investor.
“We plan to leverage Israel’s ecosystem of breakthrough science and disruptive tech innovation to accelerate cure and reshape global healthcare.” said co-founder and managing partner Yair Schindel.
aMoon I healthcare fund was capped at US$200 million from the fund’s co-founder Marius Nacht. It invested in 19 portfolio companies including Apos Therapy, BiondVax, Mapi Pharma, DayTwo, Medial EarlySign, Pharma Two B, Regenera.